Chibuzo O'Suoji1, Jennifer J G Welch2, Sherrie L Perkins3, Lynette M Smith4, Sheila Weitzman5, Stephen J Simko6, Paul J Galardy7, Catherine M Bollard8, Thomas G Gross9, Amanda M Termuhlen10. 1. Division of Pediatric Hematology/Oncology, West Virginia University, Charleston, West Virginia. 2. Division of Pediatric Hematology/Oncology, Hasbro Children's Hospital, Alpert Medical School Brown University, Providence, Rhode Island. 3. Department of Pathology, University of Utah Health Sciences, Salt Lake City, Utah. 4. Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska. 5. Division of Pediatric Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada. 6. Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas. 7. Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota. 8. Children's National Health System, The George Washington University, Washington, District of Columbia. 9. National Cancer Institute, Rockville, Maryland. 10. Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND: Non-Hodgkin lymphoma (NHL) is a relatively common malignancy in pediatric patients; however, a small subgroup have unusual lymphoma subtypes for the pediatric population. PROCEDURE: The Children's Oncology Group Rare and Cutaneous NHL registry's (protocol ANHL 04B1) main objectives were to determine the pathologic, biologic, and clinical features of rare and cutaneous pediatric NHL and establish a bank of centrally reviewed tissue specimens. We report the clinical data, treatment data, and outcome for rare pediatric NHL. RESULTS: In 101 lymphomas, there is a 97.8% concordance between the reviewing study pathologists and an 87.6% concordance between the central and institutional pathology review. Samples in the specimen bank include primary tumor tissue that is snap frozen, in paraffin blocks, or H&E-stained and unstained paraffin slides as well as blood, serum, and bone marrow. This descriptive analysis shows that children with pediatric follicular lymphoma, mucosa-associated lymphoid tissue, nodal marginal zone lymphoma, primary cutaneous, primary central nervous system lymphoma, and subcutaneous panniculitis-like T-cell lymphomas have 100% survival at a median of 2 years from enrollment. There are early deaths, mostly from progressive disease, in subjects with peripheral T-cell (not otherwise specified), NKT, and hepatosplenic T-cell lymphomas. CONCLUSIONS: This registry provides high-quality biologic specimens with clinical data to investigators working on the biology of these unusual pediatric diseases.
BACKGROUND:Non-Hodgkin lymphoma (NHL) is a relatively common malignancy in pediatric patients; however, a small subgroup have unusual lymphoma subtypes for the pediatric population. PROCEDURE: The Children's Oncology Group Rare and Cutaneous NHL registry's (protocol ANHL 04B1) main objectives were to determine the pathologic, biologic, and clinical features of rare and cutaneous pediatric NHL and establish a bank of centrally reviewed tissue specimens. We report the clinical data, treatment data, and outcome for rare pediatric NHL. RESULTS: In 101 lymphomas, there is a 97.8% concordance between the reviewing study pathologists and an 87.6% concordance between the central and institutional pathology review. Samples in the specimen bank include primary tumor tissue that is snap frozen, in paraffin blocks, or H&E-stained and unstained paraffin slides as well as blood, serum, and bone marrow. This descriptive analysis shows that children with pediatric follicular lymphoma, mucosa-associated lymphoid tissue, nodal marginal zone lymphoma, primary cutaneous, primary central nervous system lymphoma, and subcutaneous panniculitis-like T-cell lymphomas have 100% survival at a median of 2 years from enrollment. There are early deaths, mostly from progressive disease, in subjects with peripheral T-cell (not otherwise specified), NKT, and hepatosplenic T-cell lymphomas. CONCLUSIONS: This registry provides high-quality biologic specimens with clinical data to investigators working on the biology of these unusual pediatric diseases.
Authors: Andishe Attarbaschi; Oussama Abla; Leila Ronceray; Shweta Bansil; Simon Bomken; Birgit Burkhardt; Francecso Ceppi; Alan K S Chiang; Hema Dave; Alina Fedorova; Michael Henry; Janez Jazbec; Edita Kabickova; Rishi S Kotecha; Jelena Lazic; Jan Loeffen; Natalia Miakova; Tomoo Osumi; Marta Pillon; Apostolos Pourtsidis; Charlotte Rigaud; Gevorg Tamamyan; Sneha Tandon; Anne Uyttebroeck; Jamie Verdu-Amoros; Wilhelm Woessmann; Grazyna Wrobel; Lisa Giulino-Roth Journal: Blood Adv Date: 2019-12-23
Authors: Nader Kim El-Mallawany; Mercy Mutai; Idah Mtete; Satish Gopal; Christopher C Stanley; Peter Wasswa; Mary Mtunda; Mary Chasela; William Kamiyango; Jimmy Villiera; Yuri Fedoriw; Nathan D Montgomery; George N Liomba; Coxcilly Kampani; Robert Krysiak; Katherine D Westmoreland; Maria H Kim; Jeremy S Slone; Michael E Scheurer; Carl E Allen; Parth S Mehta; Peter N Kazembe Journal: Glob Pediatr Health Date: 2017-06-23
Authors: Michael G Ozawa; Aparna Bhaduri; Karen M Chisholm; Steven A Baker; Lisa Ma; James L Zehnder; Sandra Luna-Fineman; Michael P Link; Jason D Merker; Daniel A Arber; Robert S Ohgami Journal: Mod Pathol Date: 2016-06-24 Impact factor: 7.842